Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autonomy: Posdinemab in Early Alzheimer's Disease
NCT04619420Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of posidinemab in Alzheimer's disease (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Integrated Alzheimer's Disease Rating Scale Total Score at 104 weeks. Started Jan 2021; status: terminated.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04619420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619420.